Zentalis Pharmaceuticals Inc (ZNTL) Directors and Executive Officers

Officers & Directors

1. Kimberly Blackwell, M.D.
Chief Executive Officer and Director - (principal executive officer)

2. Melissa B. Epperly
Chief Financial Officer - (principal financial and accounting officer)

3. Skvarka
Director -

4. David M. Johnson
Chairperson -

5. Enoch Kariuki
Director -

6. Karan S. Takhar
Director -

7. Cam S. Gallagher
President and Director - ,

Zentalis Pharmaceuticals Inc currently has 106 employees.

News about Zentalis Pharmaceuticals Inc Key Personnel

Zentalis Pharmaceuticals: Navigating Leadership Changes Amid Financial Struggles and Strategic Talent Acquisition

In a whirlwind of activity, Zentalis Pharmaceuticals finds itself at a pivotal juncture, marked by significant executive leadership changes, alarming financial metrics, and an aggressive strategy to attract top talent. These developments are essential to understanding the company s trajectory as it seeks to secure a foothold in the highly competitive biopharmaceutical landscape.Leadership TransformationThe recent appointment of Julie Eastland as the new Chief Executive Officer, President, and Director signals a strategic shift in Zentalis Pharmaceuticals approach to corporate governance and operational execution. Such changes at the executive level often reflect a company’s urgent need for fresh perspect...

Zentalis Pharmaceuticals Appoints Accomplished Oncologist, Dr. Diana Hausman, as Chief Medical Officer in a Bid to Overcome Market Downturn.

Zentalis Pharmaceuticals Bolsters Leadership Team and Aims to Reverse Market Downturn
In an effort to navigate through a challenging market period, Zentalis Pharmaceuticals Inc. has made significant strides in strengthening its management team with key appointments. The company has recently announced the addition of Dr. Diana Hausman, an accomplished oncologist and drug developer, to its ranks as the new Chief Medical Officer. This strategic move comes at a time when Zentalis Pharmaceuticals shares are currently trading on the NASDAQ at a staggering -34% below its 52-week average.
Dr. Hausman brings a wealth of experience and expertise to her role as Chief Medical Officer at Zentalis Pharmaceuticals...